Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP

Genes and Development

Volumn 14, Issue 3, 2000, Pages 272-277

  Kung, Andrew L ^a   Rebel, Vivienne I ^a   Bronson, Roderick T ^b   Ch'ng, Lian Ee ^a   Sieff, Colin A ^a   Livingston, David M ^a   Yao, Tso Pang ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CBP; Hematopoiesis; LoH; p300; Tumor suppressor

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROTEIN P300;

ALLELISM; ARTICLE; CANCER INHIBITION; DOSE RESPONSE; EMBRYO; EMBRYO DEVELOPMENT; GENE DOSAGE; GENE LOCUS; HEMATOPOIESIS; HETEROZYGOSITY LOSS; LEUKEMIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CREB-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HETEROZYGOTE; LOSS OF HETEROZYGOSITY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR PROTEINS; PHENOTYPE; SPLEEN; TRANS-ACTIVATORS;

EID: 0034141475     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1988. Current protocols in molecular biology. Wiley-Interscience, New York, NY.
2. Bannister, A.J. and T. Kouzarides. 1996. The CBP co-activator is a histone acetyltransferase. Nature 384: 641-643.
3. Blobel, G.A., T. Nakajima, R. Eckner, M. Montminy, and S.H. Orkin. 1998. CREB-hinding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc. Natl. Acad. Sci. 95: 2061-2066.
4. Borrow, J., V.J. Stanton, J.M. Andresen, R. Becher, F.G. Behm, R.S. Chaganti, C.I. Civin, C. Disteche, I. Duhe, A.M. Frischauf et al. 1996. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 14: 33-41.
5. Caporossi, D. and S. Bacchetti. 1990. Definition of adenovirus type 5 functions involved in the induction of chromosomal aberrations in human cells. J. Gen. Virol 71: 801-808.
6. Drews, R., M. Kolker, C. Moran, D. Sachar, V. Chan, and L. Schnipper. 1998. Genetic analysis of adenovirus E1A: Induction of genetic instability and altered cell morphologic and growth characteristics are segregatable functions. Mutat. Res. 421: 9-15.
7. Eckner, R. 1996. p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol. Chem. 377: 685-688.
8. Eckner, R., Z. Arany, M. Ewen, W. Sellers, and D.M. Livingston. 1994. The adenovirus E1 A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. Cold Spring Harb. Symp. Quant. Biol. 59: 85-95.
9. Facchini, L.M. and L.Z. Penn. 1998. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights. FASEB J. 12: 633-651.
10. Fero, M.L., E. Randel, K.E. Gurley, J.M. Roberts, and C.J. Kemp. 1998. The murine gene p27Kipl is haplo-insufficient for tumour suppression. Nature 396: 177-180.
11. Frith, C.H., J.M. Ward, and M. Chandra. 1993. The morphology, immunohistochemistry, and incidence of hematopoietic neoplasms in mice and rats. Toxicol Pathol 21: 206-218.
12. Giles, R.H., D.J. Peters, and M.H. Breuning. 1998. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14: 178-183.
13. Gu, W. and R.G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
14. Harlow, E. and D. Lane. 1988. Antibodies: A laboratory manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
15. He, T.C., A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, P.J. Morin, B. Vogelstein, and K.W. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
16. Miller, R.W. and J.H. Rubinstein. 1995. Tumors in Rubinstein-Taybi syndrome. Am. J. Med. Genet. 56: 112-115.
17. Muraoka, M., M. Konishi, R. Kikuchi-Yanoshita, K. Tanaka, N. Shitara, J.M. Chong, T. Iwama, and M. Miyaki. 1996. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12: 1565-1569.
18. Nakajima, T., C. Uchida, S.F. Anderson, C.G. Lee, J. Hurwitz, J.D. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90: 1107-1112.
19. Ogryzko, V.V., R.L. Schiltz, V. Russanova, B.H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959.
20. Oike, Y., A. Hata, T. Mamiya, T. Kaname, Y. Noda, M. Suzuki, H. Yasue, T. Naheshima, K. Araki, and K. Yamamura. 1999a. Truncated CBP protein leads to classical rubinstein-tayhi syndrome phenotypes in mice: Implications for a dominant-negative mechanism. Hum. Mol. Genet. 8: 387-396.
21. Oike, Y., N. Takakura, A. Hata, T. Kaname, M. Akizuki, Y. Yamaguchi, H. Yasue, K. Araki, K. Yamamura, and T. Suda. 1999b. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood 93: 2771-2779.
22. Petrij, F., R.H. Giles, H.G. Dauwerse, J.J. Saris, R.C. Hennekam, M. Masuno, N. Tommerup, O.G. van, R.H. Goodman, D.J. Peters et al. 1995. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348-351.
23. Potter, M. 1997. Experimental plasmacytomagenesis in mice. Hematol Oncol. Clin. North Am. 11: 323-347.
24. Rebel, V.I., S. Hartnett, G.R. Hill, S.B. Lazo-Kallanian, J.L.M. Ferrara, and C.A. Sieff. 1999. Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J. Exp. Med. 190: 1493-1505.
25. Redner, R.L., J. Wang, and J.M. Liu. 1999. Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 94: 417-428.
26. Shikama, N., L. Lyon, and N.B. La Thangue. 1997. The p300/CBP family: Integrating signals with transcription factors and chromatin. Trends. Cell Biol. 7: 230-236.
27. Sohulo, O.M., J. Borrow, R. Tomek, S. Reshmi, A. Harden, B. Schlegelbcrger, D. Housman, N.A. Doggett, J.D. Rowley, and L.N. Zeleznik. 1997. MLL is fused to CBP, a histone acetyltransferase, in therapyrelated acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. 94: 8732-8737.
28. Svensson, C., M. Bondesson, E. Nyberg, S. Linder, N. Jones, and G. Akusjarvi. 1991. Independent transformation activity by adenovirus-5 E1 A-conserved regions 1 or 2 mutants. Virology 182: 553-561.
29. Tanaka, Y., I. Naruse, T. Maekawa, H. Masuya, T. Shiroishi, and S. Ishii. 1997. Abnormal skeletal patterning in embryos lacking a single Cbp allele: A partial similarity with Rubinstein-Taybi syndrome. Proc. Natl. Acad. Sci. 94: 10215-10220.
30. Waltzer, L. and M. Bienz. 1998. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 395: 521-525.
31. Whyte, P., N.M. Williamson, and E. Harlow. 1989. Cellular targets for transformation by the adenovirus E1A. Cell 56: 67-75.
32. Yang, X.J., V.V. Ogryzko, J. Nishikawa, B.H. Howard, and Y. Nakatani. 1996. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319-324.
33. Yao, T.P., G. Ku, N. Zhou, R. Scully, and D.M. Livingston. 1996. The nuclear hormone receptor coactivator SRC-I is a specific target of p300. Proc. Natl. Acad. Sci. 93: 10626-10631.
34. Yao, T.P., S.P. Oh, M. Fuchs, N.D. Zhou, L.E. Ch'ng, D. Newsome, R.T. Bronson, E. Li, D.M. Livingston, and R. Eckner. 1998. Gene dosagedependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93: 361-372.